Open AccessGranulocyte‐Macrophage Colony‐stimulating Factor Augments Lymphokine‐activated Killer Activity from Pleural Cavity Mononuclear Cells of Lung Cancer Patients without Malignant Effusion
Author(s) -
Takahashi Keiji,
Sone Saburo,
Saito Seiya,
Kamamura Yoshitaka,
Uyama Tadashi,
Ogura Takeshi,
Monden Yasumasa
Publication year - 1995
Publication title -
japanese journal of cancer research
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 2.035
H-Index - 141
eISSN - 1349-7006
pISSN - 0910-5050
DOI - 10.1111/j.1349-7006.1995.tb03097.x
Subject(s) - medicine , peripheral blood mononuclear cell , lung cancer , lymphokine activated killer cell , lymphokine , pleural effusion , immunology , malignant pleural effusion , granulocyte macrophage colony stimulating factor , cytokine , granulocyte , colony stimulating factor , pathology , in vitro , immune system , biology , stem cell , t cell , haematopoiesis , biochemistry , genetics , interleukin 21
The role of recombinant granulocyte‐macrophage colony‐stimulating factor (GM‐CSF) in augmentation of lymphokine‐activated killer (LAK) cell induction by interleukin‐2 (IL‐2) from pleural cavity mononuclear cells (PCMNCs) was examined in sixteen patients with resectable primary lung cancer not associated with malignant effusion. None of the patients had received any anticancer therapy prior to this study. Incubation of PCMNCs of patients without malignant effusion with GM‐CSF for 4 days in the presence of IL‐2 resulted in a significant increase in LAK activity against natural killer‐resistant Daudi cells. This result was obtained by using the 4 h 51 Cr‐release assay. PCMNCs and blood mononuclear cells (BMNCs) were harvested simultaneously from pleural cavity lavage fluid and peripheral blood in lung cancer patients. The LAK activity developed from PCMNCs and BMNCs following incubation with IL‐2 for 4 days, but the LAK activity from PCMNCs was significantly lower than that from BMNCs ( P < 0.05). Incubation of PCMNCs with GM‐CSF augmented the LAK activity from PCMNCs to a level as high as that from BMNCs. These results suggest that the combined use of GM‐CSF with IL‐2 may result in augmentation of LAK activity developed from PCMNCs of lung cancer patients without malignant effusion.